abbvie glp-1 receptor agonist Enters Obesity Field, Paying $350M for Amylin Already in the Clinic Repurposing glucagon-like peptide-1 receptor agonists
Description
Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes
doi: 10.1055/a-2266-1503
PKCDRS, and PKC-DRS 2 Study Groups
Limited clinical data hinder confident conclusions despite positive findings in animal models
The biology and pharmacology of GLP-1 GLP-1 is a major peptide hormone of the incretin system
Even among patients with diabetes, where the clinical case for continued treatment was strongest, 46.5 percent stopped within 12 months
